SUS Public Consultation Evaluates High-Cost Medication for Hypertension

The opening of a public consultation until August 17 to incorporate a continuous-use medication for adults with severe forms of pulmonary hypertension redefines the debate on financial sustainability and resource allocation within the Unified Health System (SUS). While the financial market monitors the Selic rate target set at 14.00% per year, the supplementary and public health ecosystem debates the fiscal pressure generated by complex treatments with high financial impact on patients' lives. The discussion gains urgency in an environment where the 12-month accumulated IPCA registers a variation of 4.44% (with 7-day trend fluctuations pointing to 4.23% and the 30-day reading at -4.31%), highlighting the chronic need for rigorous budgetary control by the State. In the current macroeconomic landscape, the commercial dollar quoted at R$ 5.2236 — accumulating a 2.12% rise over a 7-day horizon and a 0.73% positive variation in 30 days — exerts direct pressure on the import of active pharmaceutical ingredients (APIs) and reference drugs. This unfavorable exchange rate scenario exponentially increases the cost of the hospital supply chain, forcing public managers to recalculate margins and technological incorporation schedules. The volatility of the US currency, driven by external factors and the domestic risk premium, turns any high-cost drug incorporation decision into a stress test for public accounts and long-term fiscal balance. This editorial analysis consolidates the sixth consecutive challenging or negative biased agenda in our recent archive on the Economic Policy axis, adding to recent discussions on sovereignty, exchange rates, political friction, and electoral fiscal risks. From the perspective of the credit cycle and structural liquidity, we frame this event within the current stage of monetary tightening and budgetary restriction, where every real allocated to new demands requires equivalent cuts or fiscal decompression in other areas. The school of structural macroeconomics demonstrates that the expansion of continuous obligations by the State, without the proper counterpart of revenues or operational efficiency gains, compresses the space for productive investments and generates systemic imbalances. The potential incorporation of drugs for rare and severe diseases generates a multiplier effect on the Union's budget, requiring deep cost-effectiveness and actuarial sustainability analyses. With the basic interest rate parked at 14.00% per year, the opportunity cost of public capital reaches high levels, making the financing of operational deficits excessively burdensome for the National Treasury. The risk lies in judicialization and corporate pressure on the public treasury, factors that can disrupt the medium and long-term financial planning of the Ministry of Health if strict escalation criteria and aggressive patent negotiations are not applied. Over the 30-day horizon, the closure of the public consultation and the consolidation of civil society's technical contributions are projected, with a high probability of intense polarization between patient associations and fiscal managers. For the 90-day horizon, medium probability expectations point to the issuance of a preliminary opinion by Conitec (National Commission for the Incorporation of Technologies in the SUS), guided by exchange rate behavior and the stability of the dollar around R$ 5.22. In the 180-day horizon...